Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
+$0.06 today
- Market cap
- $148.58M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
Volume 1.71M
Average 1.12M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Abeona Therapeutics Inc.
NASDAQ:ABEO
Intrinsic Alpha fair value
Locked
Current Price
$2.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +11.6% (5yr)1 analysts |
| Revenue | N/A | N/A | +60.3% | +124.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | +10.2% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +60.3% over three years. Forward estimates point to Revenue at +124.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Assembly Biosciences, Inc. NASDAQ:ASMB | $430.02M | $21.12 | Not rated | -64.4 | -37.31% |
Puma Biotechnology, Inc. NASDAQ:PBYI | $401.70M | $7.77 | Overvalued | 15.4 | +41.11% |
Sagimet Biosciences Inc. NASDAQ:SGMT | $332.99M | $10.22 | Not rated | -5.0 | +25.96% |
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | $240.96M | $8.36 | Not rated | -2.7 | +20.39% |
Eledon Pharmaceuticals, Inc. NASDAQ:ELDN | $171.87M | $2.12 | Not rated | -5.5 | +28.57% |
Humacyte, Inc. NASDAQ:HUMA | $155.12M | $0.56 | Not rated | -1.9 | -58.25% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $124.12M | $2.07 | Not rated | -3.8 | -63.55% |
Voyager Therapeutics, Inc. NASDAQ:VYGR | $107.66M | $1.73 | Not rated | -1.9 | -64.49% |
Tenaya Therapeutics, Inc. NASDAQ:TNYA | $79.59M | $0.35 | Not rated | -1.3 | -74.78% |
Continue the stock analysis
Jump to another research area for this company.